Inner Ear

ENT and Allergy Associates, LLP Board of Directors has selected Daniel Blum, MPA as its new Chief Executive Officer

Retrieved on: 
Tuesday, November 29, 2022
Human voice, Trustee, MPA, LLP, Phelps Memorial Hospital, Weill Cornell Medical Center, Hospital, Mount Sinai Hospital, Audiology, Asthma, ENT, White Plains Hospital, American Academy of Facial Plastic and Reconstructive Surgery, St. Vincent Hospital, Norwegian Asthma and Allergy Association, Partnership, Northwell Health, Physician, JAMA Facial Plastic Surgery, The Advisory Board Company, Patient, Montefiore Medical Center, Disorder, Sleep, Grace Medical Center (Baltimore), Gold, Sinai Hospital, American Cancer Society, Dizziness, Inner Ear, Health administration, Health, LifeBridge Health, EVP, Management, Medicine, New York University, Philosophy, MD

Tarrytown, New York, Nov. 29, 2022 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA) the largest ENT, Allergy, and Audiology practice in the country is pleased to announce that Daniel Blum, MPA has been appointed as its new Chief Executive Officer, effective February 27, 2023.

Key Points: 
  • Tarrytown, New York, Nov. 29, 2022 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA) the largest ENT, Allergy, and Audiology practice in the country is pleased to announce that Daniel Blum, MPA has been appointed as its new Chief Executive Officer, effective February 27, 2023.
  • Daniel Blum will succeed Robert Glazer who is stepping down from the CEO role after 25 years.
  • The Board is excited and looks forward to working with Dan and the senior management team to build on the companys momentum.
  • Dan is a thoughtful communicator and a resourceful and strategic-minded healthcare veteran with substantial experience working at the executive and board level.

ENT and Allergy Associates, LLP Wins NextGen 2022 Excellence in Healthcare Award for their Implementation of the RCxRules Revenue Cycle Engine

Retrieved on: 
Monday, November 21, 2022
Automation, LLP, Workflow, Northwell Health, American Academy of Facial Plastic and Reconstructive Surgery, Asthma, Ear, Disorder, American Cancer Society, Inner Ear, ENT, Physician, Partnership, NextGen Healthcare, Operation, Allergy, Mount Sinai Hospital, Dizziness, Intersect ENT, Nose, Patient, UGM, RCM, Risk, Sleep, Revenue cycle management, Montefiore Medical Center, Nextgen, Norwegian Asthma and Allergy Association, Human voice, Health insurance, Health care

WHITE PLAINS, N.Y., Nov. 21, 2022 /PRNewswire/ -- ENT and Allergy Associates, LLP (ENTA) the largest ear, nose, throat, allergy, and audiology practice in the country, was recognized by NextGen Healthcare with a 2022 Excellence in Healthcare award for their implementation of the RCxRules Revenue Cycle Engine .

Key Points: 
  • WHITE PLAINS, N.Y., Nov. 21, 2022 /PRNewswire/ -- ENT and Allergy Associates, LLP (ENTA) the largest ear, nose, throat, allergy, and audiology practice in the country, was recognized by NextGen Healthcare with a 2022 Excellence in Healthcare award for their implementation of the RCxRules Revenue Cycle Engine .
  • The selection was made at the annual NextGen User Group Meeting in Nashville, TN.
  • NextGen hosted 1,800 healthcare professionals from all specialties at this year's UGM.
  • Congratulations to Margaret Hargrove and the Revenue Cycle Management and Operations teams at ENTA for a successful rollout of the RCxRules Revenue Cycle Engine, which has helped them to improve their financial performance while streamlining their workflow.

ENT and Allergy Associates, LLP Acquires Totum Health Lisa A. Liberatore, MD Transitions the Care of Patients to the Practice’s Upper East Side Office

Retrieved on: 
Tuesday, September 13, 2022
Northwell Health, Human voice, American Cancer Society, Disorder, American Academy of Facial Plastic and Reconstructive Surgery, Injection, Allergy, Inner Ear, MD, Asthma, JAMA Facial Plastic Surgery, SF, Partnership, Nose, Patient, History, Norwegian Asthma and Allergy Association, LLP, Physician, Mount Sinai Hospital, Sleep, CEO, Otorhinolaryngology, Dizziness, ENT, 86th Street (Manhattan), Retirement, Ear, GLOBE, Medicine, Montefiore Medical Center, Hospital, Dentistry

Dr. Liberatore, an independent New York-based Otolaryngologist, will transition the care of her patients from her Upper East Side practice to the physicians of ENT and Allergy Associates.

Key Points: 
  • Dr. Liberatore, an independent New York-based Otolaryngologist, will transition the care of her patients from her Upper East Side practice to the physicians of ENT and Allergy Associates.
  • Her commitment to continued quality care for her patients helped drive her decision to transfer their care to ENT and Allergy Associates, LLP.
  • Patients of Dr. Liberatore can now be seen by ENTA physicians at the practices Upper East Side office, conveniently located at 210 East 86th Street, New York, NY.
  • Totum Healths patients, and all Upper East Side patients alike, will soon have the opportunity to receive care in this new state-of-the-art facility.

ENT and Allergy Associates, LLP Further Strengthens Its Allergy Division Welcomes Fellowship-Trained Allergist/Immunologist Niha Qamar, MD

Retrieved on: 
Friday, September 9, 2022
Partnership, University, Private practice, ENT, Dizziness, Norwegian Asthma and Allergy Association, Northwell Health, LLP, Asthma, Mount Sinai Hospital, Otorhinolaryngology, Â, Human voice, Internal medicine, Physician, Sleep, Inner Ear, American Cancer Society, Montefiore Medical Center, Investment, Disorder, MD, GLOBE, Interstate 495 (New York), Population, Hofstra University, Doctor of Audiology, Adult, ST, Growth, Renaissance School of Medicine at Stony Brook University, Allergist, CCC, University of California, Davis, American Academy of Facial Plastic and Reconstructive Surgery, Patient, Medicine, Hospital, Medical device, Allergy, Fresh

Tarrytown, New York, Sept. 09, 2022 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA) offers each of their patients same-day access to board-certified and fellowship-trained allergists/immunologists.

Key Points: 
  • Tarrytown, New York, Sept. 09, 2022 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA) offers each of their patients same-day access to board-certified and fellowship-trained allergists/immunologists.
  • Dr. Niha Qamar, who joins ENTA from private practice, will begin seeing patients in the groups Fresh Meadows, Queens office effective January 1, 2023.
  • Dr. Niha Qamar completed her bachelors degree at St. Johns University and graduated with her doctorate from Stony Brook University School of Medicine.
  • As a board-certified Allergist, Dr. Qamar treats both pediatric and adult patients for all types of allergic and immunologic conditions.

InteliChart's Healthy Outcomes Selected by ENT and Allergy Associates as its New Patient Engagement Platform

Retrieved on: 
Tuesday, August 9, 2022
API, Mount Sinai Hospital, Otorhinolaryngology, Asthma, Inner Ear, Human voice, Sleep, CEO, Norwegian Asthma and Allergy Association, Northwell Health, Dizziness, American Cancer Society, EHR, Hospital, Nextgen, Health, American Academy of Facial Plastic and Reconstructive Surgery, NextGen Healthcare, LLP, Allergy, Patient, Montefiore Medical Center, Patient portal, EHealth, Partnership, Disorder, ENT, Practice management, Goal, Solution, EPM, Health insurance, Medicine

CHARLOTTE, N.C., Aug. 9, 2022 /PRNewswire/ -- Leading patient engagement and consumer healthcare provider InteliChart is pleased to announce that ENT and Allergy Associates, LLP (ENTA) has selected InteliChart's Patient Portal from the Healthy Outcomes patient engagement platform to optimize their patient engagement and consumer healthcare initiatives.

Key Points: 
  • CHARLOTTE, N.C., Aug. 9, 2022 /PRNewswire/ -- Leading patient engagement and consumer healthcare provider InteliChart is pleased to announce that ENT and Allergy Associates, LLP (ENTA) has selected InteliChart's Patient Portal from the Healthy Outcomes patient engagement platform to optimize their patient engagement and consumer healthcare initiatives.
  • "We are excited that ENTA has selected InteliChart's Healthy Outcomes Platform to ensure they deliver a patient experience consistent with their established reputation.
  • InteliChart delivers Healthy Outcomes, the market-leading patient-engagement platform that helps providers attain superior patient outcomes.
  • The Healthy Outcomes platform consists of Patient Portal, Family Portal, Patient Intake, Patient Notify, Patient Survey, Patient Schedule, Patient Activate, and Patient eHealth.

ENT and Allergy Associates® Welcomes Otolaryngologist/Laryngologist Corina Din-Lovinescu, DO, to Shrewsbury, NJ Office

Retrieved on: 
Friday, July 22, 2022
Allergy, New Jersey Medical School, Northwell Health, LLP, National, Disorder, Time, GLOBE, Human, Dysphagia, Population, Physician, Jersey Shore, Touro College of Osteopathic Medicine, Maintenance, Otorhinolaryngology, CEO, Hearing, Partnership, Ear, American Academy of Facial Plastic and Reconstructive Surgery, Montefiore Medical Center, National Human Genome Research Institute, Gold, Mount Sinai Hospital, Adult, ENT, Dizziness, DO, American Cancer Society, Norwegian Asthma and Allergy Association, Dartmouth College, Sleep, Human voice, Asthma, Patient, Inner Ear, FACS, Nose, Osteopathic medicine in the United States, Hospital, Dentistry, Medical device, MD, Central Jersey

Tarrytown, New York, July 22, 2022 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA) proudly announces that Corina Din-Lovinescu, DO, will join its Shrewsbury, New Jersey office effective October 1, 2022.

Key Points: 
  • Tarrytown, New York, July 22, 2022 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA) proudly announces that Corina Din-Lovinescu, DO, will join its Shrewsbury, New Jersey office effective October 1, 2022.
  • Dr. Din-Lovinescu, a fellowship-trained Laryngologist, will provide care alongside ENTAs 300+ board-certified ear, nose, throat, allergy, and audiology providers.
  • The addition of Dr. Din-Lovinescu to our Shrewsbury office, and our Practice, will allow us to serve our patients better and more effectively.
  • About ENT & Allergy Associates, LLP:
    ENT and Allergy Associates LLP (ENTA) has more than 240 physicians practicing in over 55 office locations in Westchester, Putnam, Orange, Dutchess, Rockland, Queens, Nassau, and Suffolk counties, as well as New York City and northern/central New Jersey.

ENT and Allergy Associates Conducting Clinical Trial of Investigational LYR-210 Treatment for Chronic Rhinosinusitis (CRS) Patients

Retrieved on: 
Wednesday, June 15, 2022
Dizziness, Allergy, Otorhinolaryngology, Mount Sinai Hospital, LLP, Therapy, Safety, Lyra, Inflammation, American Cancer Society, Tissue, III, Pharmacotherapy, Ohio Drive, American Academy of Facial Plastic and Reconstructive Surgery, Asthma, Northwell Health, Sinusitis, ENT, Inner Ear, Trial of the century, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Physician, Disorder, Pain, Norwegian Asthma and Allergy Association, Sleep, Audiology, Montefiore Medical Center, Human voice, Partnership, CRS, Nose, Patient, Paranasal sinuses, Academic health science centre, GLOBE, Ear, Common, Pharmaceutical industry, Dentistry

This clinical study will be led by Dr. Moshe Ephrat, who is at the forefront of clinical research.

Key Points: 
  • This clinical study will be led by Dr. Moshe Ephrat, who is at the forefront of clinical research.
  • The Lake Success office, which is located at 6 Ohio Drive, Lake Success, NY, 11042, is currently screening and enrolling subjects for this clinical study.
  • Dr. Ephrat has academic appointments as an Assistant Clinical Professor for the Zucker School of Medicine at Hofstra/Northwell.
  • Chronic rhinosinusitis (CRS) is a common condition defined by symptomatic inflammation of the paranasal sinuses lasting longer than 12 weeks.

ENT and Allergy Associates Conducting Clinical Trial of Investigational LYR-210 Treatment for Chronic Rhinosinusitis (CRS) Patients

Retrieved on: 
Thursday, June 9, 2022
American Academy of Facial Plastic and Reconstructive Surgery, Ohio Drive, American Cancer Society, Norwegian Asthma and Allergy Association, Audiology, ENT, III, Dizziness, Common, Inflammation, Nose, Mount Sinai Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Paranasal sinuses, Allergy, Partnership, Lyra, Pain, Asthma, Therapy, Disorder, Physician, Sinusitis, Sleep, GLOBE, Patient, Northwell Health, Pharmacotherapy, Trial of the century, Ear, Montefiore Medical Center, CRS, Otorhinolaryngology, Academic health science centre, Tissue, Human voice, LLP, Inner Ear, Safety, Pharmaceutical industry, Dentistry

This clinical study will be led by Dr. Moshe Ephrat, who is at the forefront of clinical research.

Key Points: 
  • This clinical study will be led by Dr. Moshe Ephrat, who is at the forefront of clinical research.
  • The Lake Success office, which is located at 6 Ohio Drive, Lake Success, NY, 11042, is currently screening and enrolling subjects for this clinical study.
  • Dr. Ephrat has academic appointments as an Assistant Clinical Professor for the Zucker School of Medicine at Hofstra/Northwell.
  • Chronic rhinosinusitis (CRS) is a common condition defined by symptomatic inflammation of the paranasal sinuses lasting longer than 12 weeks.

ENT and Allergy Associates® Welcomes Fellowship-Trained Allergist/Immunologist Aaron Westreich, M.D.

Retrieved on: 
Tuesday, May 24, 2022
Physician, Fellow, Immunology, Human voice, Population, American Academy of Facial Plastic and Reconstructive Surgery, University of Maryland School of Medicine, ENT, Norwegian Asthma and Allergy Association, Patient, Northwell Health, Practice, Audiology, Otorhinolaryngology, American Cancer Society, Asthma, Maryland School, Adult, Dizziness, University of Minnesota, LLP, Sleep, Partnership, Allergy, Inner Ear, University, Disorder, Mount Sinai Hospital, Medical degree, National Jewish Health, Montefiore Medical Center, CEO, GLOBE, Medicine, Hospital, Medicine, Immunotherapy, Ear

Tarrytown, New York, May 24, 2022 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA) is pleased to announce the recruitment of Aaron Westreich, M.D.

Key Points: 
  • Tarrytown, New York, May 24, 2022 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA) is pleased to announce the recruitment of Aaron Westreich, M.D.
  • Effective July 1st, ENTA and Ear, Nose & Throat Associates of New York will combine to substantially increase access to high-quality Otolaryngology, Allergy and Audiology services throughout the Bronx, Queens, and Long Island.
  • To learn more about the benefits of ENT and Allergy Associates, or to conveniently find an ENT or Allergy doctor and then easily book an appointment at the nearest New York or New Jersey location, please visit www.entandallergy.com or call 1-855-ENTA-DOC.
  • About ENT & Allergy Associates, LLP
    ENT and Allergy Associates LLP (ENTA) has more than 235 physicians practicing in 58 office locations in Westchester, Putnam, Orange, Dutchess, Rockland, Nassau, and Suffolk counties, as well as New York City and northern/central New Jersey.

Acousia Therapeutics to present its first-in-class hearing loss treatment program with ACOU085 at the 2nd Inner Ear Therapeutics Summit in Boston

Retrieved on: 
Wednesday, May 11, 2022
Molecule, Small molecule, Early, Treatment, Solution, Clinic, Hanson, Hearing loss, Expected shortfall, Patient, Inner Ear, Sensorineural hearing loss, Gesellschaft mit beschränkter Haftung, Mind the gap, Therapy, Pharmaceutical industry

ACOU085 is a proprietary, first-in-class, small-molecule otoprotective drug candidate, which is currently being tested in a Phase 1b clinical trial involving age-related hearing loss (ARHL) patients.

Key Points: 
  • ACOU085 is a proprietary, first-in-class, small-molecule otoprotective drug candidate, which is currently being tested in a Phase 1b clinical trial involving age-related hearing loss (ARHL) patients.
  • Designed to modulate a biologically validated target the KCNQ4-encoded Kv7.4 potassium channel, which is essential for maintaining auditory function ACOU085 is being developed for the treatment and prevention of hearing loss for a number of acquired and inherited forms of sensorineural hearing loss.
  • "Being invited to share the translational background and progress of our ACOU085 lead program with the hearing loss drug development community at the Inner Ear Therapeutics Summit is an exciting opportunity for us," says Dr.Jonas Dyhrfjeld-Johnsen, Chief Development Officer at Acousia Therapeutics.
  • The company is dedicated to the identification and development of small molecules for effective prevention and treatment of different etiologies of hearing loss.